m<sup>6</sup>A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY. · 2019
Read m<sup>6</sup>A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. by Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6592937.txt.
Introduction
Yang and co-authors show that an RNA demethylase helps melanoma grow and dodge immunotherapy, writing in Nature Communications. The enzyme is FTO, which erases m6A marks from messenger RNA. It runs high in human melanoma, speeds tumor growth in mice, and is itself switched on by starvation stress through autophagy and NF-κB signaling.
FTO's erasing protects three pro-tumor genes: PD-1 itself, CXCR4 and SOX10. Knocking FTO down restored their m6A marks, and the reader YTHDF2 then destroyed those messages. Melanoma cells grew more sensitive to interferon gamma, and tumors in mice responded far better to anti-PD-1 blockade. The authors propose pairing an FTO inhibitor with checkpoint therapy to crack resistance.
Catalog record
| CREATOR | Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, Aplin AE, Lu Z, Hwang S, He C, He YY. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade By Seungwon Yang, Jiangbo Wei, Yan-Hong Cui, Gayoung Park, Palak Shah, Yu Deng, Andrew E Aplin, Zhike Lu, Seungmin Hwang, Chuan He, Yu-Ying He Published in: Nature Communications DOI: 10.1038/s41467-019-10669-0 ABSTRACT Abstract Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade immunotherapy. FTO level is increased in human melanoma and enhances melanoma tumorigenesis in mice. FTO is induced by metabolic starvation stress through the autophagy and NF-κB pathway. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma (IFNγ) and sensitizes melanoma to anti-PD-1 treatment in mice, depending on adaptive immunity. Our findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma. Subject terms: Cancer, Oncogenes, Skin cancer, Melanoma INTRODUCTION Melanoma is one of the most deadly and therapy-resistant human cancers in the United States1. The incidence of melanoma continues to rise at an alarming rate each year, faster than any of the other common cancers2. In the past decades, tremendous progress has been made in elucidating the mechanism of melanoma development at the molecular, cellular and organismal levels1. Both genetic, including mutations in oncogenes and tumor suppressor genes, and epigenetic mechanisms, including DNA methylation, microRNAs, and other non-coding RNAs, have been demonstrated to play critical roles in melanoma pathogenesis1,3–5. In particular, the discoveries of BRAF mutations and their functions in most melanomas have led to the development of molecular therapy targeting the mutant BRAF1. However, the majority of the patients treated with an inhibitor of mutant BRAF eventually suffer continuous disease progression6. Recent breakthroughs in immunotherapy, including anti-PD-1 checkpoint blockade therapy, have benefitted a growing number of melanoma patients7–9. Still, more than half of these patients do not show a durable response to immunotherapy. Multiple mechanisms, such as driver mutations, epigenetic mechanisms, tumor plasticity, and immunosuppression, may cooperate to maintain the melanoma phenotype and mediate resistance to therapies, including immunotherapy10,11, which makes targeting a single pathway less effective. Our understanding of the molecular mechanisms for melanoma development and therapeutic response is still limited. An emerging molecular mechanism regulating gene expression at the post-transcription level is N6-methyladenosine (m6A) RNA methylation. m6A RNA methylation is the most prominent chemical modification found in messenger RNA (mRNA) and non-coding RNA in eukaryotic cells12–15. Recently, the first m6A demethylase FTO was discovered, suggesting that m6A RNA methylation is reversible and dynamic and may have crucial physiological and pathological functions16. Subsequently, two studies independently mapped the transcriptome-wide m6A distribution17,18. These studies also suggest that, similar to the reversible epigenetic modifications to DNA and histone, post-transcriptional methylation of adenosines in RNA provides an epitranscriptomic layer of regulation that may control mRNA fate and gene expression. In the past several years, compelling evidence has demonstrated that m6A methylation plays critical roles in controlling RNA metabolism and function in physiological processes and stress response. m6A modification regulates development, stem cell homeostasis, response to stresses such as heat-shock and genotoxic damage, and control of the circadian clock19–22. m6A modification regulates RNA fate and such functions as mRNA stability, nuclear processing, transport, localization, translation, primary microRNA processing, and RNA-protein interactions23–28. m6A modulators have been shown to play important roles in several cancers by regulating cancer-type-specific target genes and functions19,20, suggesting the unique regulatory and functional significance of the intrinsic m6A mRNA modifications and their regulators in different cancers. Recent work has also suggested that the genetic variations of FTO are associated with increased melanoma risk in humans29,30. The association of these FTO variations in exon 8 with melanoma risk seems to be independent of body mass index (BMI)29,30. As the first m6A demethylase identified, FTO has been show to act as an oncogenic factor in leukemia31,32 and glioblastoma33. However, the role of FTO as an m6A eraser in melanoma pathogenesis and response to anti-melanoma therapies remains poorly understood. Here we report that the m6A demethylase FTO regulates melanoma growth and mediates melanoma resistance to anti-PD-1 antibody in vitro and in vivo. Our results identify a unique FTO-mediated and m6A-mediated mechanism in promoting melanoma tumorigenesis and resistance to anti-PD-1 blockade, and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce resistance and improve the anti-melanoma response. RESULTS FTO as a protumorigenic factor in melanoma To determine the role of FTO in human melanoma, we first analyzed FTO protein levels specifically in the melanocytes of normal human skin and malignant melanoma samples using immunofluorescence. We used MART1 immunofluorescence co-staining (Green) to specifically identify melanocytes in normal skin and melanoma cells (Fig. 1a). FTO (Red) was low in epidermal melanocytes in normal skin (n = 16), while it was significantly increased in all diagnoses of melanoma, including metastasis (n = 64), primary melanoma (n = 36), and melanoma at stages I–IV (n = 65) (Fig. 1a, b). There was no significant difference in FTO levels between different diagnosis groups of melanomas except between Stage I and IV. Next, we determined the FTO protein levels in normal human epidermal melanocytes (NHEM) and a panel of melanoma cell lines. FTO remained unchanged in WM35 (BRAF mutation, Human) cells (Fig. 1c). However, it was up-regulated in six of the tested cell lines, particularly in Mel624 (BRAF mutation, Human) and B16F10 (BRAF wild-type, Mouse) cells, two aggressive model melanoma cell lines, as well as WM115 (BRAF mutation, Human), WM793 (BRAF mutation, Human), WM3670 (BRAF and NRAS mutation, Human), and CHL-1 (BRAF and NRAS wild-type, Human) (Fig. 1c). These results demonstrate that FTO is upregulated in human melanoma samples and multiple melanoma cell lines, suggesting a protumorigenic role of FTO in melanoma development. [Figure: FTO is upregulated in human melanoma. a Immunofluorescence staining of FTO and MART1 in normal human skin and melanoma tissues. Nuclei are counterstained with DAPI in blue. Scale bar, 50 μm. The arrows indicate representative melanocytes in normal human epidermis. b Percentage of tumors (in stacked column format) for each score of FTO. 0 (Negative), 1 (Weak), 2 (Medium), and 3 (Strong); *P < 0.05; **P < 0.01; ****P < 0.0001; ns, P > 0.05, not significant; Mann–Whitney U-test. c Immunoblot analysis of the protein levels of FTO, and β-actin (loading control) in normal melanocytes and melanoma cells] To determine the biological function of FTO in melanoma cells, we performed both gain- and loss-of-function studies in melanoma cells (Fig. 2a). Knockdown of FTO in FTO-high Mel624, CHL-1, and B16F10 cells decreased cell growth/proliferation, migration, invasion, and cell viability in cells placed in suspension (Fig. 2b–e, and Supplementary Fig. 1a–n). In addition, FTO knockdown also decreased cell invasiveness in 3D culture with Matrigel and colony formation in soft agar, respectively (S1O-S1S). Overexpression of FTO markedly increased cell proliferation, cell migration, invasion, and cell viability in cells in suspension (Fig. 2b–e, and Supplementary Fig. 1d) in WM35 with an FTO protein